Select therapeutic use:
Indications for HUMULIN N:
Adults and Children:
SC injection only. Onset approx 1–2hrs, peak 6–12hrs, duration 18–24hrs.
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction.
Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Onset may be delayed if regular insulin is mixed with zinc insulin. Regular and NPH insulins may be mixed and used immediately or stored for future use.
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.
Vials 70/30, N, R (U-100)—10mL; R (U-500)—20mL; KwikPen (70/30, N)—5x3mL; R (U-500)—2x3mL, 5x3mL